Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 1, 2012, Pages 82-93

  Franchini, Massimo ^a   Tagliaferri, Annarita ^a   Mengoli, Carlo ^b   Cruciani, Mario ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Center of Community Medicine   (Italy)

Author keywords

Bleeding; FVIII concentrates; Inhibitors; Plasma derived; Recombinant; Systematic review; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; REVIEW; SIDE EFFECT; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HUMANS; PLASMA; RECOMBINANT PROTEINS;

EID: 84855912746     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.002     Document Type: Review

References (112)

1. Tuddenham E.G., Mannucci P.M. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001, 344:1773-1779.
2. Franchini M., Coppola A., Molinari A.C., et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 2009, 15:578-586.
3. Leissinger C.A. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006, 12(Suppl. 6):67-73.
4. Coppola A., Franchini M., Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009, 101:674-681.
5. Gringeri A., Mantovani L.G., Scalone L., Mannucci P.M. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-2363.
6. Gomperts E.D. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors. Haemophilia 2006, 12:573-578.
7. Hay C.R. The epidemiology of factor VIII inhibitors. Haemophilia 2006, 12(Suppl. 6):23-29.
8. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010, 16(Suppl. 2):10-15.
9. Escuriola Ettingshausen C., Kreuz W. Recombinant versus plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006, 12(Suppl. 6):102-106.
10. Scharrer I., Bray G.L., Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999, 5:145-154.
11. Wight J., Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003, 9:418-435.
12. Scharrer I., Neutzling O. Incidence of inhibitors in haemophiliacs. a review of the literature. Blood Coagul Fibrinolysis 1993, 4:753-758.
13. Sharrer I., Neutzling O., Schwaab R., Oldenburg J., Ehrlich H. Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol 1998, 76(Suppl. 1):A1-6.
14. Briet E., Rosendaal F.R., Kreuz W., et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994, 72:162-164.
15. Astermark J. Overview of inhibitors. Semin Hematol 2006, 43(2 Suppl.):S3-S7.
16. Oldenburg J., Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006, 12(Suppl. 6):15-22.
17. Goodeve A. The incidence of inhibitor development according to specific mutations - and treatment?. Blood Coagul Fibrinolysis 2003, 14(Suppl. 1):S17-21.
18. Calvez T., Laurian Y., Goudemand J. Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. J Thromb Haemost 2008, 6:390-392.
19. Franchini M., Lippi G. VWF-containing FVIII concentrates and inhibitors in hemophilia a: a critical literature review. Thromb Haemost 2010, 104. [Epub ahead of print].
20. Navarrete A.M., Dasgupta S., Teyssandier M., et al. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. Thromb Haemost 2010, 104. [Epub ahead of print].
21. Iorio A., Halimeh S., Holzhauer S., et al. Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010, 8:1256-1265.
22. Favaloro E.J., Bonar R., Kershaw G., Duncan E., Sioufi J., Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009, 35:794-805.
23. White G.C., Rosendaal F., Aledort L.M., Lusher J.M., Rothschild C., Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001, 85:560.
24. Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics 1990, 46:1171-1178.
25. von Elm E., Altman D.G., Egger M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
26. Vandenbroucke J.P., von Elm E., Altman D.G., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4(10):e297.
27. Wells G.A., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2010, Available at (last visit 14.10.2010). http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
28. Lusher J.M., Salzman P.M. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in haemophiliacs previously unexposed to factor VIII C concentrates. Semin Hematol 1990, 27(Suppl. 2):1-7.
29. Lusher J.M. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIII:C. Ann Hematol 1991, 63:138-141.
30. Ehrenforth S., Kreuz W., Scharrer I., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-598.
31. Ljung R., Petrini P., Lindgren A., Tengborn L., Nilsson I.M. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:1550.
32. Addiego J.E.-J., Gomperts E., Liu S.L., et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII:C immunoaffinity chromatography. Thromb Haemost 1992, 67:19-27.
33. de Biasi R., Rocino A., Papa E., Salerno E., Mastrullo L., De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994, 71:544-547.
34. Yee T.T., Williams M.D., Hill F.G., Lee C.A., Pasi K.J. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997, 78:1027-1029.
35. El Alfy M.S., Tantawy A.A., Ahmed M.H., Abdin I.A. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Thromb Haemost 2000, 6:635-638.
36. Mauser-Bunschoten E.P., van der Bom J.G., Bongers M., et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 2001, 7:364-368.
37. Kreuz W., Ettingshausen C.E., Zyschka A., et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Haemost 2002, 28:285-290.
38. Bray G.L., Gomperts E.D., Courter S.G. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients. Blood 1997, 83:2428-2435.
39. Gruppo R., Chen H., Schroth P., Bray G.L. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients: a 7.3 year update. Haemophilia 1998, 4:228. [abstract no. 291, XXIII Congress of the WFH, The Hague].
40. Goodeve A.C., Williams I., Bray G.L., Peake I.R. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000, 83:844-848.
41. Rothschild C., Laurian Y., Satre E.P., et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998, 80:779-783.
42. Lusher J.M., Arkin S., Abildgaard C.F., Schwartz R.S. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. Safety, efficacy and development of inhibitors. Kogenate previously untreated patient study group. N Engl J Med 1993, 328:453-459.
43. Lusher J., Abildgaard C., Arkin S., et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004, 2:574-583.
44. Yoshioka A., Fukutake K., Takamatsu J., Shirahata A. Evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003, 78:467-474. Kogenate Post-Marketing Surveillance Study Group.
45. Giangrande P.L.F. Safety and efficacy of Kogenate Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002, 8(Suppl. 2):19-22. for the Kogenate Bayer Study Group.
46. Kreuz W., Gill J.C., Rothschild C., et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005, 3:457-467.
47. Oldenburg J., Ivaskevicius V., Schröder J., Müller C.R., Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost 2006, 95:903-905.
48. Musso R., Santagostino E., Faradji A., et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008, 99:52-58.
49. Lusher J.M., Lee C.A., Kessler C.M., Bedrosian C.L. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003, 9:38-49.
50. Lusher J.M., Roth D.A. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia: an update. Haemophilia 2005, 11:292-293.
51. Courter S.G., Bedrosian C.L. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001, 38:52-59.
52. Pollmann H., Externest D., Ganser A., et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007, 13:131-143.
53. Schwarzinger I., Pabinger I., Korninger C., et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987, 24:241-245.
54. McMillan C.W., Shapiro S.S., Whitehurst D., Hoyer L.W., Rao A.V., Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988, 71:344-348.
55. Schwartz R.S., Abildgaard C.F., Aledort L.M., et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990, 323:1800-1805.
56. Rasi V., Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990, 76:369-371.
57. Fukui H., Yoshioka A., Shima M., et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol 1991, 54:419-427.
58. Fukui H., Mori K., Ishikawa M., et al. A long-term, multi-center clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. Nihon Yuketsu Gakkai Zasshi 1991, 37:593-604.
59. Lorenzo J.I., Garcia R., Molina R. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:1550-1551.
60. Addiego J., Kasper C., Abildgaard C., et al. Inhibitors in factor VIII deficient hemophilia: comparison of frequency based upon treatment. Blood 1992, 80(Suppl. 1):231. [abstract].
61. Sultan Y. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. The French Hemophilia Study Group. Thromb Haemost 1992, 67:600-602.
62. Rosendaal F.R., Nieuwenhuis H.K., van den Berg H.M., et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993, 81:2180-2186.
63. Peerlinck K., Rosendaal F.R., Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993, 81:3332-3335.
64. Addiego J., Kasper C., Abildgaard C., et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993, 342:462-464.
65. Peerlinck K., Arnout J., Gilles J.G., Saint-Remy J.M., Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993, 69:115-118.
66. Schimpf K., Schwarz P., Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995, 73:553-555.
67. Guerois C., Laurian Y., Rothschild C., et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly-purified plasma-derived concentrate. Thromb Haemost 1995, 73:215-218.
68. Kamiya T., Takahashi I., Saito H. Retrospective study of inhibitor formation in Japanese hemophiliacs. Int J Hematol 1995, 62:175-181.
69. White G.C.I.I., Courter S., Bray G.L., Lee M., Gomperts E.D. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997, 77:660-667.
70. Muntean W., Male Ch, Streif W., et al. Low inhibitor incidence in children treated with pasteurised human factor VIII. Thromb Haemost 1997, (Suppl. 1):647. [abstract].
71. Aygoren-Pursun E., Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997, 78:1352-1356. German Kogenate Study Group.
72. Lusher J., Arkin S., Abildgaard C., Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A-update of safety, efficacy and inhibitor development after 7 study years. Thromb Haemost 1997, 78(Suppl.):162. [abstract].
73. Peerlinck K., Arnout J., Di Giambattista M., et al. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus-inactivated plasma-derived factor VIII concentrate. Thromb Haemost 1997, 77:80-86.
74. Giles A.R., Rivard G.E., Teitel J., Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transf Sci 1998, 19:139-148.
75. Goudemand J., D'Oiron R., Rothschild C., et al. Incidence des inhibiteurs anti-F VIII chez des patients traits par facteur VIII-LFB. Sang Thromb Vaiss 1998, 10:77-81.
76. Baglin T., Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?. Thromb Haemost 1998, 80:1036-1037.
77. Seremetis S., Lusher J.M., Abildgaard C.F., Kasper C.K., Allred R., Hurst D. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999, 5:9-16.
78. Lusher J.M., Kreuz W., Gazengel C., et al. Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rFVIII concentrate formulated with sucrose. Blood 1999, 94(Suppl. 1):237A. [abstract].
79. Rokicka-Milewska R., Klukowska A., Dreger B., Beer H.J. Incidence of factor VIII inhibitor development in previously untreated haemophilia A patients after exposure to a double virus inactivated factor VIII concentrate. Ann Haematol 1999, 78(Suppl. 1):A10. [abstract].
80. Yee T.T., Pasi K.J., Lilley P.A., Lee C.A. Factor VIII inhibitors in haemophiliacs: a single centre experience over 34 years, 1964-97. Br J Haematol 1999, 104:909-914.
81. Abshire T.C., Brackmann H.H., Scharrer I., et al. Sucrose formulated recombinant human antihemophilic factor VIII is safer and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000, 83:811-816.
82. Shirahata A., Fukutake K., Takamatsu J., Shima M., Yoshioka A. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol 2000, 72:101-107.
83. Yoshioka A., Shima M., Fukutake K., Takamatsu J., Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001, 7:242-249. Coganate FS Study Group.
84. Lorenzo J.I., Lopez A., Altisent C., Aznar J.A. Incidence of factor VIII inhibitors in severe haemophilia: the importance of age. Br J Haematol 2001, 113:600-603.
85. Rothschild C., Scharrer I., Brackmann H.H., et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002, 8(Suppl. 2):10-14.
86. Van der Bom J.G., Mauser-Bunschoten E.P., Fischer K., van den Berg H.M. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003, 89:475-479.
87. Gringeri A., Tagliaferri A., Tagariello G., et al. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004, 126:398-404.
88. Ewenstein B.M., Gomperts E.D., Pearson S., O'Banion M.E. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004, 10:491-498.
89. Tarantino M.D., Collins P.W., Hay C.R., et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004, 10:428-437.
90. Morado M., Villar A., Jiménez Yuste V., Quintana M., Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005, 11:79-83.
91. Smith M.P., Giangrande P., Pollman H., et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005, 11:444-451.
92. Kreuz W., Auerswald G., Budde U., Lenk H. Inhibitor development in previously untreated patients (PUPs) with haemophilia A and B. A prospective multicentre study of the German, Swiss and Austrian Society of Thrombosis and Haemostasis Research (GTH). 35th Haemophilia Symposium, Hamburg, 2004 2005, 34-37. the GTH-PUP-Study Group, Springer Verlag, Heidelberg. I. Scharrer, W. Schramm (Eds.).
93. Gringeri A., Monzini M., Tagariello G., Scaraggi F.A., Mannucci P.M. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 2006, 12:128-132. the EMOCLOT15 Study Members.
94. Goudemand J., Rothschild C., Demiguel V., et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 2006, 107:46-51.
95. Kempton C.L., Soucie J.M., Abshire T.C. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006, 4:2576-2581.
96. Gouw S.C., van den Berg H.M., le Cessie S., van der Bom J.G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-1390.
97. Shi J., Zhao Y., Wu J., Sun J., Wang L., Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 2007, 13:351-356.
98. Singleton E., Smith J., Kavanagh M., Nolan B., White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost 2007, 98:1188-1192.
99. Chalmer E.A., Chalmers E.A., Brown S.A., et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007, 13:149-155.
100. Gouw S.C., van der Bom J.G., Auerswald G., Ettinghausen C.E., Tedgård U., van den Berg H.M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-4697.
101. Delumeau J.C., Ikegawa C., Yokoyama C., Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost 2008, 100:32-37.
102. Rubinger M., Lillicrap D., Rivard G.E., et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008, 14:281-286.
103. Boekhorst J., Lari G.R., D'Oiron R., et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008, 14:729-735.
104. Blanchette V.S., Shapiro A.D., Liesner R.J., et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008, 6:1319-1326.
105. Strauss T., Ravid B., Martinowitz U., Bashari D., Kenet G. Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study. Haemophilia 2008, 14(Suppl. 2):52. [abstract].
106. Bajwa N., Enriquez M.M., Gorina E., Lemm G. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII. Haemophilia 2009, 15:597-600.
107. Young J.H., Liu H.C., Hsueh E.J., et al. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A. Haemophilia 2009, 15:968-970.
108. Recht M., Nemes L., Matysiak M., et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009, 15:869-880.
109. Bidlingmaier C., Manner D., Halimeh S., et al. Influence of factor VIII products, viral inactivation and dosage regimens on meaningful inhibitor development in children with severe hemophilia A: results of a non-concurrent cohort study. J Thromb Haemost 2009, 7(Suppl. 2):525. [abstract].
110. Mannucci P.M., Abshire T., Dimichele D., et al. Inhibitor development, immune tolerance and prophylaxis in haemophilia A-the need for an evidence-based approach. Haemophilia 2006, 12:429-434.
111. Mannucci P.M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010, 8:288-291.
112. Mannucci P.M., Gringeri A., Peyvandi F., Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007, 13(Suppl. 5):65-68.